EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis

Abstract Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be determined. This study...

Full description

Saved in:
Bibliographic Details
Main Authors: Ao Liu, Xiaoming Wang, Lian Wang, Han Zhuang, Liubo Xiong, Xiao Gan, Qian Wang, Guanyu Tao
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Cancer
Subjects:
EGFR-TKI
Non-small cell lung cancer
Osimertinib
Lazertinib
Amivantamab
Online Access:https://doi.org/10.1186/s12885-024-13168-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13168-8

Similar Items